Belize

Reimbursed Care Access

Belize’s Misuse of Drugs Act (Chapter 103) broadly schedules classical psychedelic compounds (including psilocin/psilocybin, N,N‑dimethyltryptamine, mescaline and catch‑all clauses for tryptamine/phenethylamine derivatives) as controlled substances, meaning recreational/unsanctioned possession and supply are criminal offences. Medical ketamine is listed on Belize’s national formulary for anesthetic use, but licensed psychedelic therapeutics (e.g., Esketamine/Spravato, psilocybin or MDMA therapies) are not registered or reimbursed for psychiatric indications; authorized use of any scheduled psychedelics is limited to whatever narrow research/clinical‑trial approvals may be issued under the Act. [https://www.scribd.com/document/472787847/misuse-of-drugs-act|Misuse of Drugs Act (Belize)] [https://medlistapp.paho.org/en/list/46|Belize — National Drug Formulary (PAHO)]